News & Videos - CORTEXYME INC.

Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans. Additionally, the company’s ticker symbol on the Nasdaq Global Select Market is expected change to “QNCX”...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone pathogen P. gingivalis . The study was a...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors. “We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray’s caliber to our Board of Directors,” said David Lamond, chairperson of Cortexyme’s Board of...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors. “In conjunction with today’s acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. With the completion of the acquisition, Cortexyme appointed...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company. The...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors. “Dr. Sabbagh’s deep expertise in neurological diseases and extensive clinical development experience makes him a...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases , which is a hybrid event taking place March 15-20, 2022 in Barcelona, Spain, as well as virtually. Cortexyme’s chief medical officer Michael Detke, MD, PhD, will present new...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided an update on both proprietary preclinical research and peer-reviewed publications supporting the potential of atuzaginstat (COR388) to treat patients with high-risk oral potentially malignant disorders (OPMDs), including oral/head and neck squamous cell cancer (O/HNSCC), high-risk oral...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced results from the single ascending dose (SAD) portion of the Phase 1 clinical trial of its new drug candidate COR588, a next generation, oral, small-molecule lysine gingipain inhibitor in development for the treatment of diseases related to P. gingivalis infection. The SAD trial was designed to...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided a business update and announced key milestones for 2022. Christopher Lowe, Cortexyme’s interim chief executive officer, chief operating officer, and chief financial officer, said, “Cortexyme is committed to following the evidence as we identify the most efficient path to expand our pipeline...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that its board of directors has appointed Christopher Lowe, the company’s chief operating officer and chief financial officer, as interim chief executive officer, effective immediately. This appointment follows the departure of Casey Lynch as the company’s chief executive officer and chair of the board. Current independent board member David...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 placing a full clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303). The company plans to provide additional updates pending continued engagement with FDA. Cortexyme is immediately implementing a cost...

Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time. A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com . The webcast will be archived at that location for 90...

Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14 th Clinical Trials on Alzheimer's Disease Conference ( CTAD 2021 ) as a part of the meeting’s Late-Breaking Readout Roundtable program today, Thursday, November 11, 2021, at 11:35 a.m. Eastern Time taking place in Boston, Massachusetts, as well as virtually. The presentation will expand on previously reported top-line results that demonstrated the relationship between the reduction of...

Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14 th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Boston, Massachusetts. During the company’s 30-minute presentation, Cortexyme’s chief medical officer Michael Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, will provide additional GAIN Trial...

Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis ( P. gingivalis ). The 643-participant study in mild to moderate patients with Alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14 th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference scheduled for November 9-12, 2021, in Boston, Massachusetts, as well as virtually. Cortexyme will present results from its Phase 2/3 GAIN Trial evaluating the efficacy of its lead small molecule...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate, COR588. COR588 is a second-generation small-molecule lysine-gingipain inhibitor differentiated from the company’s lead drug candidate atuzaginstat (COR388)...